Background: Intrathecal ropivacaine is now routinely used for lower limb surgery. Adjuvants e.g. fentanyl, dexmedetomidine or morphine etc. are commonly used to prolong the intraoperative anesthesia or postoperative analgesia. The available literature lacks information on use of butorphanol and nalbuphine as adjuvants with 0.75% isobaric ropivacaine. We aimed to compare nalbuphine and butorphanol as adjuvant with isobaric ropivacaine in lower limb orthopedic surgeries.
INTRODUCTION
With advancement in drugs and technique, spinal anesthesia is now gold standard in lower limb orthopedic surgery. Various studies have clearly demonstrated advantage of neuraxial anesthesia in term of significant reduction in mortality and morbidity in comparison to general anesthesia. 1 For the last many years local anesthetic (LA) bupivacaine has been used for spinal anesthesia due to its intense block characteristics. Now-a-days, bupivacaine is slowly being replaced by newer LA including ropivacaine in lower limb and lower abdominal surgeries. [2] [3] [4] [5] Ropivacaine is a long acting amide LA, structurally very similar to other pipecoloxylidides, first synthesized by Ekenstam. 6 It is a pure s-enantiomer having less motor blockade and reduced cardiotoxicity which favors its attractiveness.
Various adjuvants have been tried to improve efficacy, duration of action and safety of LAs, but opioids are the most desired due to its prolonged analgesic action. Fentanyl, morphine, buprenorphine, butorphanol, midazolam, clonidine and dexmedetomidine have been used as adjuvants. 7, 8 Nalbuphine is an opioid, potent analgesic, structurally related to oxymorphone. It is highly lipid soluble with agonist action at κ-receptor and an antagonist activity at µ-receptor. There have been studies of neuraxial administration of nalbuphine, shown to produce significant analgesia with minimal respiratory depression. 9,10 There were safety issues regarding intrathecal uses of nalbuphine; however none of the abnormalities had been encountered through all these years and it was found to be safe for neuraxial blockade. Butorphanol is morphine type synthetic opioid analgesic and structurally related to levorphanol. It acts as an agonist on κ and mixed agonistantagonist action at µ-opioid receptors. It has been shown to improve the analgesic duration of LA and helps in decreasing analgesic utilization. [11] [12] Review of literature on nalbuphine and butorphanol with isobaric ropivacaine in adult patients is scarce. So we planned this study to compare nalbuphine and butorphanol with intrathecal isobaric ropivacaine in elective lower limb orthopedic surgeries. Primary outcome of our study was a comparison of block characteristics and duration of postoperative analgesia. Secondary outcomes includes comparison of hemodynamic parameters and adverse events, if any. orthopedic surgeries, were randomly allocated into two groups: Group RN; to receive isobaric ropivacaine (0.75%, 7.5 mg/ml) 2.5 ml plus nalbuphine 500 µg (0.5 ml), and Group RB; to receive isobaric ropivacaine 2.5 ml plus butorphanol 100 µg (0.5 ml) intrathecally. Randomization was performed by an anesthesiologist involved in studied drug preparation. Further procedure and the monitoring were performed by another investigator unaware of group allocation. Patients were also blinded to the drug regimen utilized for spinal anesthesia. In the sitting position under standard aseptic precautions, lumbar puncture was performed at L3-L4 intervertebral space in midline approach by 25 gauge Quincke spinal needle. The studied drug solution was injected over a period of 10-15 sec after the confirmation of free flow of CSF and patients were turned to the supine position. 
METHODOLOGY

RESULTS
Out of 120 patients, 108 completed study successfully (Figure 1) . Demographic profile and baseline hemodynamic parameters were comparable between two groups ( Table 1) .
Time of onset of sensory and motor block was earlier in group RN than group RB and this was significant between two groups (p < 0.05) ( Table 2) . Time required to reach median maximum height of sensory block was comparable between two groups ( Table 2) .
Duration of sensory analgesia (The time required for sensory regression to S2 level) was significantly higher in group RN than group RB (394.62 ± 31.23 vs. 316.61 ± 28.81 min) (p < 0.001) ( Table 2) . Duration of motor block was more in group RN than and this was highly significant between two groups (p < 0.001) ( Table 2) .
Intra-operative and postoperative hemodynamic parameters were comparable between two groups. Observed side effects included bradycardia, hypotension, nausea and vomiting, sedation and shivering were comparable between the two groups ( Table 3) .
DISCUSSION
Ropivacaine is a new long acting amide LA with lower risk of systemic and cardiotoxicity than bupivacaine. We conducted this trial to study the comparative efficacy of ropivacaine plus two of the adjuvants for major orthopedic lower limb surgeries as an alternative to bupivacaine. The use of adjuvants improves the intraoperative quality of anesthesia and postoperative analgesia. Studies have shown that intrathecal opioids can greatly enhance analgesia of sub-therapeutic doses of LA. We added nalbuphine and butorphanol to respective groups with ropivacaine to find out the duration of sensory analgesia and motor blockade. These drugs possess numerous pharmacologic similarities. They are both agonists of the kappa opioid receptor and partial agonists of the mu receptor. Both are equianalgesic (and nalbuphine is equipotent) with morphine parenterally and codeine orally.
Mean time of onset of sensory and motor block was significantly lower in nalbuphine group than butorphanol group. This is supported by study done by Fournier et al. 13 They studied analgesic effects of intrathecal morphine 160 µg and nalbuphine 400 µg in geriatric patients scheduled for elective total hip replacement under continuous spinal anesthesia, given in the postoperative period in the recovery room, and concluded that administration of intrathecal nalbuphine resulted in a significantly faster onset of pain relief.
Our study demonstrated that duration of analgesia, sensory and motor blockade is significantly prolonged in nalbuphine group (group RN). In a randomized, double blind, controlled study done by Sapate et al. 14 on adding intrathecal nalbuphine to bupivacaine for patients undergoing infraumblical surgeries, they concluded that intrathecal nalbuphine added to bupivacaine provided better quality of block and longer postoperative analgesia by 8-9 h than bupivacaine alone without any significant adverse effects. In a study by Tiwari et al. 15 it was shown that addition of 0.4 mg nalbuphine significantly prolongs the duration of sensory block and postoperative analgesia.
Brockway MS et al. 16 conducted a study comparing 0.5%, 0.75% and 1% ropivacaine with 0.5% and 0.75% bupivacaine. They found the mean upper limit of sensory block was T6. The above studies concluded that the highest level of sensory block was similar between nalbuphine group and butorphanol group. These findings are similar to our study.
In our study use of 500 µg nalbuphine and 100 µg butorphanol with ropivacaine resulted in moderate hypotension, requiring inj. mephentermine in both the groups after the intrathecal drug administration. Although mephentermine requirement was slightly higher in the nalbuphine group (8 in RN vs. 4 in RB), but they were not statistically significant.
LIMITATION
Our study had few limitations. First, we did not assess the surgeons' or patients' satisfaction for intrathecal nalbuphine and butorphanol. Second, the results may vary between different ethnical groups of population due to disparity in weight, height and subjective anesthetic drug sensitivity.
CONCLUSION
Both nalbuphine and butorphanol produce good postoperative analgesia without any significant adverse side effects, when used as adjuvants to isobaric 0.75% ropivacaine for spinal anesthesia in lower limb surgeries. Intrathecal nalbuphine was associated with early onset of sensory and motor block and significantly prolonged postoperative analgesia as compared to butorphanol.
